EMA Accepts Otarmeni Gene Therapy for OTOF-Related Hearing Loss for Review
If approved, Regeneron's Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union.
Tag: pharmaceuticals
All
Latest
All
Latest
FDA Approves Clotic for Otomycosis Treatment
Clotic antifungal ear therapy is scheduled for launch in the U.S. market in early 2026.
All
Latest
Sensorion Enrolls Last Patient in Clinical Trial of Drug to Prevent Cisplatin-Induced Ototoxicity
Sensorion has completed patient enrollment for its Phase 2a NOTOXIS trial, evaluating SENS-401’s potential to prevent Cisplatin-induced ototoxicity.
Sensorion Gets Positive Recommendation for Clinical Trial of Drug Candidate for Cisplatin-Induced Ototoxicity
Sensorion was recommended to continue the study of a drug candidate for the prevention of Cisplatin-Induced Ototoxicity (CIO).
Read More
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment
Cilcare granted the pharmaceutical company rights to license two promising drug candidates for hearing disorders.
Read More
Cilcare Names New Chief Medical Officer
Cilcare has appointed a new chief medical officer to oversee clinical development strategies and collaborations, leveraging his extensive experience in medical affairs and pharmaceutical industry leadership.
Read More
Frequency Therapeutics Updates Progress on Hearing Loss Treatments, Q1 2021 Financials
In the company’s announcement, Frequency Therapeutics provides updates on data from its recent FX-322 Clinical Readouts, including new information from a Phase 1b study in presbycusis, and further clarifies acquired sensorineural hearing loss target populations and future study design. The company anticipates initiating a new FX-322 Phase 2 Study in H2 2021.
Read More
AudiologyNOW! 2016 Highlights the Changing Landscape of Hearing Healthcare
This year’s AudiologyNOW! AAA event, said to be the largest annual gathering of audiologists in the world, attracted 3,408 audiologists and featured a wealth of instructional sessions and workshops at the Phoenix Convention Center.
Read More
Kathleen Campbell Updates ADA Attendees on Otoprotective Agents That Are Currently in or Approaching Clinical Trials
In the General Session of the 2014 Academy of Doctors of Audiology (ADA) Convention held November 6-9, 2014 in Las Vegas, Kathleen Campbell, PhD, of Southern Illinois University School of Medicine, gave an interesting and lively talk on ototoxicity and the role of pharmaceutical agents in hearing loss management and prevention.
Read MoreC&EN Publishes Article on Pharmaceutical Approaches to Hearing Treatment
More pharmaceutical and research companies are developing drugs to treat and prevent hearing loss, according to an April 7 article in Chemical & Engineering News (C&EN).
Read More